A program with a moderated panel discussion format that focuses on the evolving cell & gene therapy ecosystem in and around Philadelphia. The discussion will include how cell and gene therapy is different than traditional pharmaceutical manufacturing in terms of operations/logistics, facility design, quality, and regulatory considerations. We will also discuss what makes this geographical area such a potent ecosystem, attracting new companies and organizations over the past   2-3 years, as well as keeping companies here and fostering their growth. Four dynamic presenters representing different owners’ considerations will provide their insight and answer questions posed by the attendees.

Speakers:

Lauren Gilchrist – Sr. Vice President, Sr. Director of Research at JLL – Philadelphia

Responsible for the strategic direction of JLL Philadelphia’s research platform, including: development of JLL’s proprietary research data platform, economic data, demographic data, market overviews, and broker and client ad hoc requests; leading leasing and capital markets business development efforts, including investor market overviews, tenant rep and agency business development meetings, and formal pitches; leading JLL Philadelphia’s media relations strategy through the development of timely, engaging content and fielding press inquiries; creating new revenue opportunities through the development and execution of consulting assignments. Select clients include the Las Vegas Sands Corporation, the Durst Organization, and Brandywine Realty Trust.

Allison Montalvo – Executive Director, Project Management and Clinical Supply at Tmunity Therapeutics

Allison Montalvo has extensive experience in development and manufacturing of biologics, vaccines and cell-based products at established and emerging pharmaceutical and biotech companies. Currently, Allison is Executive Director, Head of Project and Portfolio Management at Tmunity Therapeutics where she is responsible for providing oversight for project leadership, product development teams, CMC teams.

Prior to Tmunity, Mrs. Montalvo worked at Merck and Teva pharmaceuticals where she held positions of increasing responsibility in product development and portfolio management leadership. She holds a BS in Genetic Engineering from Cedar Crest College.

Dunni Odumosu – Senior Director, Regulatory Affairs Gene Therapy at BridgeBio

Dunni Odumosu is a Senior Director at BridgeBio Gene Therapy and is currently working to support two programs to enter Phase 1 clinical development. Prior to joining BridgeBio, Dunni was the Global Regulatory Lead of the Fabry program at Amicus Therapeutics. In that role, Dunni worked on the company’s first marketing authorizations leading to approvals in the EU and US as well as many other countries giving Fabry patients around the world the opportunity to have a new treatment option.

In addition to her career as a rare disease regulatory professional, Dunni is passionate about empowering other women, particularly in STEM. In 2016, Dunni was asked to charter the formation of the Philadelphia Metro chapter of Women in Bio, an organization comprised of professional women from all career areas in the life sciences with the philosophy of “women helping women”. As the Chapter Chair, Dunni worked with a diverse leadership team of women from different background and levels of experience with the goal of brining like-minded women in the emerging Philadelphia biotech hub together, providing a space for meaningful connections to take place.

Beyond her career in the biotech industry, Dunni is passionate about inclusive beauty, the science of beauty and shifting the global view of Africa. She nurtures this passion as a co-host on the Beauty Needs Me podcast where they host honest discussions about beauty that crosses color, culture and country lines and in educating independent beauty brands about entering African countries.

Dunni holds a B.S. in Chemistry from Temple University and a Master of Science in Regulatory Affairs/Quality Assurance from Temple University School of Pharmacy.

Emilie Pelletier – Senior Director Process Engineering at Iovance Biotherapeutics

Emilie has been in the Life Sciences Industry for 15 years. Currently, Emilie is Senior Director, Process Engineering at Iovance Biotherapeutics, an autologous oncology cell therapy company. Previously, Emilie was the USA Managing Partner at Laporte Consultants. Her responsibilities include leading Laporte’s biopharmaceutical activities in the USA in addition to designing and implementing biotech facilities and processes. Prior to Laporte Consultants, she was a project engineer at Axcan Pharma from 2004 to 2007. Emilie has held several positions in the DVC Chapter of ISPE and is a member of the ISPE Biomanufacturing COP committee. She obtained a B.S in chemical engineering from the University of Montreal and is fluent in French and English.

Thank you to our sponsors of this event: